We pride ourselves in providing cost-effective therapeutic options for patients, especially in underserved disease segments.
Over the Counter and prescription products will be introduced in Canada and other countries. Prescription products will consist of specialized medicines with few competitors.
Our 23 wholly-owned prescription and non-prescription products are targeted to improve health-related conditions including several forms of iron deficiency, bone loss, rheumatoid arthritis, migraine headaches, urinary tract infections, infant cradle cap, joint pain and much more. Axxess Pharma intends to market these products with affordable pricing and widespread availability. Our company will continue to tap the well of innovation to develop ever-more effective and affordable treatment options for the patients we serve, and also foster innovation in education, leadership and advocacy.
Personal passion concerning the well-being of chronic illness sufferers is a major driving force and at the heart of our company. Affordable, proven, prescription and non-prescription products are a critical component to our company Business Plan. We balance environmental impact, social contribution, and financial results. Axxess Pharma is publicly traded on the US stock exchange under the ticker symbol: AXXE . Headquartered in Canada, AXXE is a specialty pharmaceutical and nutritional supplements company, that works through its wholly owned subsidiary, AllStar Health Brands Inc.
A wholly-owned subsidiary of Axxess Pharma Inc., with the licensed world-wide rights to manufacture, and distribute TapouT-branded line of Pain relief, Vitamins & Minerals and Nutritional Supplements.
New line to be sold through military exchanges
MarketWatch: Partnership with Axxess Pharma Inc.
"This is the culmination of more than a year's hard work and we are extremely grateful to Acosta, one of the largest US distributors for making this happen," stated Dr. Daniel Bagi, President of Axxess Pharma. "The Army and Air Force (AAFES) have 2,817 facilities in 30 countries, all fifty states and five US territories. These worldwide facilities include embassies and small bases where we have troops stationed-like in Sarajevo. Retail sales in their stores last year reached $9.2 Billion."
AllStar Health Brands expects TapouT products to be well-received on military bases as the TapouT brand is popular with military personnel who embrace the toughness and dedication the brand represents.
Axxess Pharma Announces Expansion of US Sales Channels
Receives Initial Purchase Order From RonnieColemanNutrition.com
Gravergol® Anti-Migraine Therapy.
Gravergol® remains the only prescription product in Axxess Pharma’s lineup of medicines. Gravergol® acts on both the pain as well as the nausea and vomiting of migraine headaches. While Gravergol® competes in a large category with well-known brands such as Imitrex® and Zomig®, Gravergol® is available at one tenth of the price of aforementioned products. Over 20 million prescriptions have been written for Gravergol®
This is testament to the product’s efficacy and safety.
Prior to the discontinuation of Gravergol® in 2009, Gravergol® was selling approximately $200k MAT.
The market size of the ergot-derivative market is estimated to be approximately $2MM.
Triferexx®was the flagship product for Axxess Pharma prior to the company entering receivership in 2009. Triferexx® was responsible for +90% of Axxess Pharma’s sales and will be re-launched as a natural health product (NHP) once Health Canada re-issues the license in 2014. Triferexx® 150 mg is a high potency (150 mg elemental oral iron) supplement. Triferexx® 150 allows for once-daily dosing while minimizing side effects such as constipation, diarrhea, upset stomach and other GI side effects which other iron supplements such as ferrous saltsmay cause. Triferexx® 150 avoids or reduces these common side effects.
The types of patients which are candidates for Triferexx® are:
• Patients suffering from blood loss • Pregnant women • Women who experience heavy menstrual bleeding • Renal failure patients, especially those undergoing dialysis • Patients suffering from low iron as a results of a disease
Triferexx® will be sold in Canada and Mexico commencing January, 2014.
Soropon® OTC Fungal Shampoo
Soropon®is an antifungal Shampoo which was selling approximately $600k MAT under previous management. Soropon® shampoo is a gentle, effective treatment for fungal infections of the scalp such as sebhorreic dermatitis and cradle cap in infants
The main competitors for Soropon® are Nizoral®, Dan-Guard®, SebCur®and Polytar®. The price range for products in this market are $20.00 - $24.00. The estimated market size of this category is $10MM.
Cancer Drugs Portfolio
AXXESS has entered into an exclusive distribution agreement with the Canadian manufacturer of a full line of approximately 12 cancer drugs for injection, and a suite of other antibiotic drugs for injection.
Biolyse Corporation, the Canadian manufacturer of this common cancer drug used in the treatment of several major cancers including breast, lung, ovarian and several others has granted the rights for Mexico and other Latin American territories to Axxess Pharma.
The key driver to the success of this business for Axxess Pharma is the price point, and Axxess has obtained a favorable price in order to compete in Mexico and other Latin American territories.
The sale of cancer drugs in the majority of Latin American markets is primarily through government tenders due to the relatively high prices of most cancer drugs.
Axxess has already an agreement in place to work with a company in Mexico with experience in government tender business and has the advantage of offering a high-quality Canadian product at a price competitive with local manufacturers and as part of the North American Free Trade Agreement is legally allowed to enter into the tender business.
Axxess expects to add up to 11 other cancer drugs to this portfolio as they become available from the Canadian manufacturer, including the expected first generic version of a major cancer drug which currently enjoys sales in Mexico of approximately US $20 MM.
Nutritional Products International (NPI) http://www.nutricompany.com/ , who handles the United States distribution for the company is excited to begin branching out the full TapouT Sports Nutrition line. NPI has the ability to reach thousands of retail outlets across the United States. The company also exports products to all seven continents.
"With TapouT Sports Nutrition products, we see nothing that can stop these products from becoming an even bigger household name than they already are," says NPI CEO, Mitch Gould. "We fully believe this line will be a huge success. If these products are good enough for some of the hardest training athletes in the world, then they will do wonders for everyone who uses them."
Revive BioScience Inc. a leader in developing private label pain relief products, for leading consumer brands and health care organizations. Revive offers a full range of pain relief products including
: •OTC Analgesic products
• OTC Topical analgesic products
• All natural pain relief supplements
• Hot & Cold Therapy products
Revive has a national distribution of products in Canada, through GNC and independent retail stores, and expects to add other large retail outlets later this year. The products Revive developed will be sold in mass retail stores across Canada (currently in market), USA and Mexico.
Further, the company has an exclusive world-wide license with one of the top sporting brands in the world. This license provides access to a global distribution network, including 20,000+ retailers. The branded products are endorsed by current athletes from the NFL, NHL and UFC.
Revive also brings a number of key operators to Axxess Pharma with extensive experience in retail and online sales. This will benefit all of the products now controlled by Axxess Pharma.
Dr. Daniel Bagi, President of Axxess Pharma Inc., stated: "We are extremely pleased and excited to announce this acquisition of Revive. Both sides have been working long and hard to finalize this acquisition, which will instantly add revenues to Axxess Pharma's bottom line. We believe we can very quickly grow sales significantly working with Revive's team through added marketing efforts. They have great products which are widely recognized. We expect this acquisition will facilitate access to capital and enable a rapid ramp-up of sales for major revenue growth in the near term."
For more information, please visit www.axxesspharmainc.com, or contact Investor Relations at (973) 351-3868.
Recently AXXE announced that with its strategic partner, Vortex Traffic LLC, there will bea nation-wide mass online launch of TapouT Muscle Explosion. Since 2007 Vortex has produced over $140 million in global sales for its clients! http://www.vortextraffic.com/
The target has isolated over 4,500 websites to launch the campaign on!
Stephen Blazick, President of Vortex Traffic LLC, stated: "TapouT continues to be Vortex's primary focus due to its scalability potential and is unlike any other partnership we have had. Our team at Vortex is target-focused on launch by mid-February and have isolated over 4,500 web sites we are planning to launch this campaign on. It will be a household name, if it is not already, within months."
AXXE has also been adding celebrity athletes on as endorsers, recently including Catia James, a cross-fit bikini competiton champion, and champion bodybuilder Michael Spencer.
Axxess Pharma Inc. (AXXE) - VNN - Daniel Bagi MD Published on Jun 27, 2013
- Goals – to reach $36 million year 4
Product mass retail across North America
Worldwide online sales distribution
World-wide exclusive license with TapouT® brand
- World leading athletic lifestyle brand - w/$350MM/yr.
Management: Proven track record, highly experienced
2013 - 2015 Forecast Product Overview
Axxess has a wide range of specialized healthcare products. Products will be launched based on priority and market demand.
Specialized products include:
- Specialized vitamins
All natural pain relief
Pain relief supplements
Interview with Axxess Pharma Inc (AXXE)
OTC Pink Current Information Common Stock AXXE Axxess Pharma, Inc.
|Market Value || || |
|Shares Outstanding || || |
|Float || |
|Authorized Shares ||3,000,000,000 || |